Treatment of High Risk Polycythemia Vera and High Risk Essential Thrombocythemia

What we are studying

The purpose of this study is to look at the effectiveness of giving participants who have been diagnosed with ET or PV one of two different study regimens over time. The study doctor would want to follow patients' condition for about 5 years. The study regimens are either ‘PEGASYS’ (or Pegylated Interferon Alfa-2a) or ‘Hydroxyurea’. All subjects participating in this study will also receive Aspirin as a part of their study regimen regardless of which study drug they will receive. More information on these study regimens will be described later in this information sheet. To enter this study patients may be a newly diagnosed subject or a subject already receiving treatment for either PV or ET. Each of the study drugs used in this study is already being used to treat subjects with ET or PV currently but we are unsure which study drug is better.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 18+

Eligibility Criteria

  • Diagnosed with Essential Thrombocythemia (ET) or Polycythemia Vera (PV)
  • Diagnosed less than 3 years prior to enrollment on the study

What is involved

  • 1 screening visit
  • Receive 1 of 2 study treatments (chosen at random) for about 2 years
  • Study visits will occur on average every 3 months but may be more frequent
  • Follow-Up visits will be every 3 months for 2 years

Compensation

None

Contact Information

Study Coordinator
Thomas Freeman
Email
thfreema@wakehealth.edu
Phone
Not Listed

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.